- Home
- ALLR vs PULM Comparison
ALLR vs PULM Comparison
Compare ALLR & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- PULM
- Stock Information
- Founded
- ALLR 2004
- PULM 2003
- Country
- ALLR United States
- PULM United States
- Employees
- ALLR N/A
- PULM N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- ALLR Health Care
- PULM Health Care
- Exchange
- ALLR Nasdaq
- PULM Nasdaq
- Market Cap
- ALLR 15.8M
- PULM 18.3M
- IPO Year
- ALLR N/A
- PULM N/A
- Fundamental
- Price
- ALLR $1.52
- PULM $5.09
- Analyst Decision
- ALLR Strong Buy
- PULM
- Analyst Count
- ALLR 1
- PULM 0
- Target Price
- ALLR $9.00
- PULM N/A
- AVG Volume (30 Days)
- ALLR 21.5M
- PULM 9.7K
- Earning Date
- ALLR 11-13-2025
- PULM 11-07-2025
- Dividend Yield
- ALLR N/A
- PULM N/A
- EPS Growth
- ALLR N/A
- PULM N/A
- EPS
- ALLR N/A
- PULM N/A
- Revenue
- ALLR N/A
- PULM $369,000.00
- Revenue This Year
- ALLR N/A
- PULM N/A
- Revenue Next Year
- ALLR N/A
- PULM $134.88
- P/E Ratio
- ALLR N/A
- PULM N/A
- Revenue Growth
- ALLR N/A
- PULM N/A
- 52 Week Low
- ALLR $0.61
- PULM $1.86
- 52 Week High
- ALLR $3.71
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- ALLR 52.13
- PULM 51.90
- Support Level
- ALLR N/A
- PULM N/A
- Resistance Level
- ALLR $1.92
- PULM $5.15
- Average True Range (ATR)
- ALLR 0.19
- PULM 0.12
- MACD
- ALLR -0.08
- PULM -0.11
- Stochastic Oscillator
- ALLR 73.79
- PULM 98.83
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).